Back to news

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

Business Wire•16/11/2026•16:01 ET
0

Key Highlights

  • ➤Cash and marketable securities $194.5 million; runway expected into fiscal 2029
  • ➤LOTUS pediatric zelicapavir enrollment complete; topline data expected 1Q 2027
  • ➤RESOLVE adult high-risk RSV trial dosing initiated; Phase 2b data expected 2027
  • ➤Fiscal 2026 revenue $63.0 million, down from $65.3 million year over year
  • ➤Enanta workforce reduced approximately one-third after strategic resource review

Expert Statements

Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals

“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027”

Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals

“With no approved antiviral therapies available to treat RSV, we believe zelicapavir is well-positioned to address a substantial unmet need across both high-risk adult and pediatric populations. As we move into late-stage development, we continue to strengthen our leadership in RSV treatment and remain urgently focused on delivering zelicapavir to patients in need.”

Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals

“In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027. We also plan to file INDs for EDP-903, our STAT6 clinical candidate, and EPS-5336, our newly selected MRGPRX2 development candidate, in the second and fourth quarters of 2027, respectively. We remain confident in our ability to deliver compounds with best-in-disease potential and look forward to multiple catalysts in the first half of next year.”

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

* Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in